-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78

Benzinga·11/04/2026 15:19:00
Listen to the news
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and lowers the price target from $89 to $78.